Myelodysplastic Syndromes and Secondary AML– Update on Diagnosis and Treatment

3 Views

06/30/23

Myelodysplastic Syndromes and Secondary AML– Update on Diagnosis and Treatment
Low-Risk MDS – Namrata Chandhok, MD, Assistant Professor, Sylvester Comprehensive Cancer Center, University of Miami
High-Risk MDS – Mikkael Sekeres, MD, MS, Professor, Sylvester Comprehensive Cancer Center, University of Miami
Panel Discussion Addressing the Gaps in Serving Patients with MDS
Irum Khan, MD, MS, Associate Professor, University of Illinois
Leyla Shune, MD, Associate Professor, Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center
Topics include the challenges of treating MDS in rural and urban settings; older patients with multiple comorbidities; barriers to care such as transportation needs, lack of support

AAMDSIF Symposium: Providing Equitable and Inclusive Care to Patients with Bone Marrow Failure Conditions
This virtual symposium provides updates on the most recent advances in the pathophysiology, diagnosis and clinical management of aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), secondary acute myeloid leukemia (AML) and hematopoietic stem cell transplantation. Additionally, the program addresses the current gaps in patient care for each of these diseases, such as clinical trial enrollment, reaching diverse patient po****tions, barriers to care, diagnostic challenges, genetic profiling, long term supportive care, and quality of life issues. The presenters represent innovative programs focusing on closing inequities and reaching underserved patient po****tions. The patient voice is incorporated through patient panelists and patient survey responses.

For more resources, please use this website link: https://www.aamds.org/professi....onals/resources-and- Please also feel free to stay up-to-date with Health Professional offering by subscribing to the professional email list at https://www.aamds.org/sign-up and select either RN or Health Professional option.